Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
CDKN2A (INK4a/ARF) is frequently disrupted in various types of human cancer, and germline mutations of this locus can confer susceptibility to melanoma and other tumours. However, because CDKN2A encodes two distinct cell cycle inhibitory proteins, p16INK4a and p14ARF (p19Arf in mice), the mechanism of tumour suppression by CDKN2A has remained controversial. Genetic disruption of Cdkn2a(p19Arf) (hereafter Arf) alone predisposes mice to tumorigenesis, demonstrating that Arf is a tumour-suppressor gene in mice. We mutated mice specifically in Cdkn2a(p16Ink4a) (hereafter Ink4a). Here we demonstrate that these mice, designated Ink4a*/*, do not show a significant predisposition to spontaneous tumour formation within 17 months. Embryo fibroblasts derived from them proliferate normally, are mortal, and are not transformed by oncogenic HRAS. The very mild phenotype of the Ink4a*/* mice implies that the very strong phenotypes of the original Ink4a/ArfDelta2,3 mice were primarily or solely due to loss of Arf. However, Ink4a*/Delta2,3 mice that are deficient for Ink4a and heterozygous for Arf spontaneously develop a wide spectrum of tumours, including melanoma. Treatment of these mice with the carcinogen 7,12-dimethylbenzanthracene (DMBA) results in an increased incidence of melanoma, with frequent metastases. Our results show that, in the mouse, Ink4a is a tumour-suppressor gene that, when lost, can recapitulate the tumour predisposition seen in humans.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mutations in p16 , Rb , ARF and TP53 are frequently found in human cancers, and their tumour-suppressive roles have been confirmed in vivo using genetically modified mouse models [25 -29].”
From The role of cellular senescence and SASP in tumour microenvironment (2023) · cites this paper as [28]
In the citing paper
“Mutations in p16 , Rb , ARF and TP53 are frequently found in human cancers, and their tumour-suppressive roles have been confirmed in vivo using genetically modified mouse models [25 -29].”
From The role of cellular senescence and SASP in tumour microenvironment (2023) · cites this paper as [28]
In the citing paper
“For example, mouse embryonic fibroblasts (MEFs) lacking p53 [72] but not Ink4a (p16) or RB [73,74,75] escape Ras-induced senescence.”
From Mechanisms and Regulation of Cellular Senescence (2021) · cites this paper as [74]
Citations
Cites
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“MEFs mutated in components of the Rb1 or Trp53 pathways are defective in various aspects of proliferative control, displaying altered proliferation rates, cell-cycle distributions and cell size compared with wild-type cell”
BackgroundTodaro, G. J., & Green, H. (1963) · The Journal of Cell Biology · doi:10.1083/jcb.17.2.299 · Cited by 2,736
Morgenstern, J. P., & Land, H. (1990) · Nucleic Acids Research · doi:10.1093/nar/18.12.3587 · Cited by 2,101
Role of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585 · cited 1×
“No melanomas were observed in DMBA-treated control animals, either in those followed by us for 8 months or in historical control”
BackgroundTumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19
Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., & Sherr, C. J. (1997) · Cell · doi:10.1016/s0092-8674(00)80452-3 · Cited by 1,566
Schwenk, F., Baron, U., & Rajewsky, K. (1995) · Nucleic Acids Research · doi:10.1093/nar/23.24.5080 · Cited by 1,289
Kiyono, T., Foster, S. A., Koop, J. I., McDougall, J. K., Galloway, D. A., & Klingelhutz, A. J. (1998) · Nature · doi:10.1038/23962 · Cited by 1,206 · cited 1×
“p16 INK4a and its downstream targets, the RB1 family members, have been implicated in this response in both huma”
BackgroundBmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF
Jacobs, J. J. L., Scheijen, B., Voncken, J.-W., Kieboom, K., Berns, A., & van Lohuizen, M. (1999) · Genes & Development · doi:10.1101/gad.13.20.2678 · Cited by 1,065
Self-citationThe p16INK4a/CDKN2A tumor suppressor and its relatives
Ruas, M., & Peters, G. (1998) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(98)00017-1 · Cited by 911
Cited by
The essence of senescence: Figure 1.
Kuilman, T., Michaloglou, C., Mooi, W. J., & Peeper, D. S. (2010) · Genes & Development · doi:10.1101/gad.1971610 · Cited by 2,038
“Genetic disruption of the gene encoding p16INK4A predisposes mice and humans to tumorigenesis, includ- ing melanoma (Gruis et al. 1995; Krimpenfort et al. 2001; Sharpless et al. 2001).”
BackgroundSelf-citationCellular senescence and the senescent secretory phenotype: therapeutic opportunities
Tchkonia, T., Zhu, Y., van Deursen, J., Campisi, J., & Kirkland, J. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64098 · Cited by 1,774
“Interfering with pathways that can induce senescence-associated replicative arrest are likely to promote cancer, as occurs when p16 INK4a , the retinoblastoma (Rb) protein, or p53 is diminished or inactivated (67, 103).”
Cellular senescence in cancer and aging.
Collado, M., Blasco, M. A., & Serrano, M. (2007) · Cell · doi:10.1016/j.cell.2007.07.003 · Cited by 1,708
“On the other hand, mice with decreased levels of p16INK4a are tumor prone, and this precludes the analysis of aging (Krimpenfort et al., 2001; Sharpless et al., 2001).”
The RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690
“Yet, mice lacking p16Ink4a, in particular, are tumor prone and develop a wide spectrum of cancers, particularly after exposure to chemical carcinogens or X-rays (Serrano et al., 1996; Krimpenfort et al., 2001; Sharpless et al., 2001).”
BackgroundGenetics and biology of pancreatic ductal adenocarcinoma
Hezel, A. F., Kimmelman, A. C., Stanger, B. Z., Bardeesy, N., & DePinho, R. A. (2006) · Genes & Development · doi:10.1101/gad.1415606 · Cited by 1,577
To cycle or not to cycle: a critical decision in cancer
Malumbres, M., & Barbacid, M. (2001) · Nature Reviews Cancer · doi:10.1038/35106065 · Cited by 1,468
Guidelines for the welfare and use of animals in cancer research
An ad hoc committee of the National Cancer Research Institute, Workman, P., Aboagye, E. O., Balkwill, F., Balmain, A., Bruder, G., Chaplin, D. J., Double, J. A., Everitt, J., Farningham, D. A. H., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605642 · Cited by 1,442
“…carcinoma Familial melanoma, sporadic pancreatic, brain tumours Crossed with Arf+/ mice Metastatic melanoma, sarcoma, carcinoma, lymphoma (Krimpenfort et al, 2001) Brca1 No tumour susceptibility Breast ovary Conditional mammaryspecific inactivation of Brca1 Mammary tumours (Xu et al,…”
BackgroundSenescent cells: an emerging target for diseases of ageing
Childs, B. G., Gluscevic, M., Baker, D. J., Laberge, R.-M., Marquess, D., Dananberg, J., & van Deursen, J. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.116 · Cited by 1,284
Pancreatic cancer biology and genetics
Bardeesy, N., & DePinho, R. A. (2002) · Nature Reviews Cancer · doi:10.1038/nrc949 · Cited by 1,142
“The INK4A transcript displays a highly restricted expression pattern and is dispensable for normal development and homeostasi”
BackgroundA Senescence Program Controlled by p53 and p16INK4a Contributes to the Outcome of Cancer Therapy
Schmitt, C. A., Fridman, J. S., Yang, M., Lee, S., Baranov, E., Hoffman, R. M., & Lowe, S. W. (2002) · Cell · doi:10.1016/s0092-8674(02)00734-1 · Cited by 1,050
Aguirre, A. J., Bardeesy, N., Sinha, M., Lopez, L., Tuveson, D. A., Horner, J., Redston, M. S., & DePinho, R. A. (2003) · Genes & Development · doi:10.1101/gad.1158703 · Cited by 1,033
“Mice with constitutive deletion of both or either component of the Ink4a/Arf locus do not develop spontaneous pancreatic adenocarcinoma; however, the rapid onset of lymphomas and sarcomas in these mice may preclude the study of more latent effects of deletions of this locus on pancreatic neoplasia (Serrano et al. 1996…”
BackgroundThe signals and pathways activating cellular senescence
Ben-Porath, I., & Weinberg, R. A. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.10.013 · Cited by 1,046
Pathways of apoptotic and non-apoptotic death in tumour cells
Okada, H., & Mak, T. W. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1412 · Cited by 1,044
“For example, mutant mice carrying cells that are incapable of entering senescence develop cancer at an early ag”
BackgroundPrinciples of Tumor Suppression
Sherr, C. J. (2004) · Cell · doi:10.1016/s0092-8674(03)01075-4 · Cited by 1,034
Geriatric muscle stem cells switch reversible quiescence into senescence
Sousa-Victor, P., Gutarra, S., García-Prat, L., Rodriguez-Ubreva, J., Ortet, L., Ruiz-Bonilla, V., Jardí, M., Ballestar, E., González, S., Serrano, A. L., et al. (2014) · Nature · doi:10.1038/nature13013 · Cited by 1,010
Kotake, Y., Nakagawa, T., Kitagawa, K., Suzuki, S., Liu, N., Kitagawa, M., & Xiong, Y. (2011) · Oncogene · doi:10.1038/onc.2010.568 · Cited by 1,001
“…website (http://www.nature.com/onc) N IH -PA Author M anuscript N IH -PA Author M anuscript mutations targeting each gene individually support the tumor suppression function for all three genes (Serrano et al., 1996; Kamijo et al., 1997; Krimpenfort et al., 2001, 2007; Sharpless et al., 2001).”
BackgroundThe INK4a/ARF network in tumour suppression
Sherr, C. J. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35096061 · Cited by 996
“Recently derived Ink4a -null mice (retaining a functional Arf ) are prone to tumour developmen”
BackgroundModelling the molecular circuitry of cancer
Hahn, W. C., & Weinberg, R. A. (2002) · Nature Reviews Cancer · doi:10.1038/nrc795 · Cited by 944
Regulation of the INK4b–ARF–INK4a tumour suppressor locus: all for one or one for all
Gil, J., & Peters, G. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1987 · Cited by 843
“Mice that are defective for any one of the genes have increased susceptibility to spontaneous or carcinogen-induced tumours, albeit to different degree”
BackgroundCyclin D-dependent kinases, INK4 inhibitors and cancer
Ortega, S., Malumbres, M., & Barbacid, M. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00037-9 · Cited by 778
Tumor suppression by Ink4a-Arf: progress and puzzles.
Lowe, S. W., & Sherr, C. J. (2003) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(02)00013-8 · Cited by 699
Epigenetic Antagonism between Polycomb and SWI/SNF Complexes during Oncogenic Transformation
Wilson, B. G., Wang, X., Shen, X., McKenna, E. S., Lemieux, M. E., Cho, Y.-J., Koellhoffer, E. C., Pomeroy, S. L., Orkin, S. H., & Roberts, C. W. M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.09.006 · Cited by 654
“However, downregulation of p16 is unlikely to be the full mechanism by which SNF5 loss drives cancer formation as tumor onset occurs much more quickly, with higher penetrance, and in a different spectrum following Snf5 inactivation than p16 inactivation (Krimpenfort et al., 2001; Sharpless et al., 2001).”
Oncogenic Braf Induces Melanocyte Senescence and Melanoma in Mice
Dhomen, N., Reis-Filho, J. S., da Rocha Dias, S., Hayward, R., Savage, K., Delmas, V., Larue, L., Pritchard, C., & Marais, R. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.02.022 · Cited by 594
“, 2005), so we examined whether Braf could also stimulate metastatic melanomas in p16 null animals by crossing the Braf/CreERT2 mice onto a p16 null background (note that these mice still express p19 [Krimpenfort et al., 2001]).”
BackgroundThe biology of CML blast crisis
Calabretta, B., & Perrotti, D. (2004) · Blood · doi:10.1182/blood-2003-12-4111 · Cited by 592
Comparative biology of mouse versus human cells: modelling human cancer in mice
Rangarajan, A., & Weinberg, R. A. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1235 · Cited by 567
“Senescent MEFs also show an increase in the levels of Ink4a; however, MEFs from Ink4a -null or Rb -null embryos succumb to both culture- and RAS -induced senescenc”
BackgroundSpecies- and cell type-specific requirements for cellular transformation
Rangarajan, A., Hong, S. J., Gifford, A., & Weinberg, R. A. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.07.009 · Cited by 555
“…transformation or p53 (Harvey et al., 1993; Kamijo et al., 1997), but not Ink4a in the two species and from different tissue compartments and or Rb (Krimpenfort et al., 2001; Sage et al., 2000; Sharpless et al., suggest possible limitations of some rodent experimental sys- 2001), have been…”
BackgroundGuerra, C., Collado, M., Navas, C., Schuhmacher, A. J., Hernández-Porras, I., Cañamero, M., Rodriguez-Justo, M., Serrano, M., & Barbacid, M. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.05.011 · Cited by 516
“Mice K-Ras+/LSLG12Vgeo;Elas-tTA/tetO-Cre (Guerra et al., 2007), p16Ink4a/ p19Arflox/lox (Krimpenfort et al., 2001), and Trp53lox/lox (Jonkers et al., 2001) strains have been described.”
Malignant melanoma: genetics and therapeutics in the genomic era
Chin, L., Garraway, L. A., & Fisher, D. E. (2006) · Genes & Development · doi:10.1101/gad.1437206 · Cited by 511
“…et al. 2001; Sharpless et al. 2001, GENES & DEVELOPMENT 2151 2002), this Ink4a-dependent susceptibility was significantly enhanced in the setting of Arf haploinsufficiency (Krimpenfort et al. 2001), arguing for an independent contribution from Arf in Ink4a/Arf-mediated melanoma suppression.”
BackgroundInfluentialDifferent telomere damage signaling pathways in human and mouse cells
Smogorzewska, A., & de Lange, T. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf433 · Cited by 482
“, 1999), which develop tumors rapidly due to the absence of p19Arf and also lack a second tumor suppressor, p16 (Serrano et al., 1996; Krimpenfort et al., 2001; Sharpless et al., 2001; Sherr, 2001).”
BackgroundTelomeres, stem cells, senescence, and cancer
Sharpless, N. E., & DePinho, R. A. (2004) · Journal of Clinical Investigation · doi:10.1172/jci20761 · Cited by 473
Trithorax group proteins: switching genes on and keeping them active
Schuettengruber, B., Martinez, A.-M., Iovino, N., & Cavalli, G. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3230 · Cited by 456
“The cellular senescence checkpoint acts as a barrier to cellular transformation”
BackgroundRaf proteins and cancer: B-Raf is identified as a mutational target
Mercer, K. E., & Pritchard, C. A. (2003) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(03)00016-7 · Cited by 457
INK4a/ARF: A multifunctional tumor suppressor locus
Sharpless, N. E. (2005) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2004.08.021 · Cited by 442
Control of the replicative life span of human fibroblasts by p16 and the polycomb protein Bmi-1
Itahana, K., Zou, Y., Itahana, Y., Martinez, J.-L., Beausejour, C., Jacobs, J. J. L., van Lohuizen, M., Band, V., Campisi, J., & Dimri, G. P. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.1.389-401.2003 · Cited by 438
Monitoring Tumorigenesis and Senescence In Vivo with a p16INK4a-Luciferase Model
Burd, C. E., Sorrentino, J. A., Clark, K. S., Darr, D. B., Krishnamurthy, J., Deal, A. M., Bardeesy, N., Castrillon, D. H., Beach, D. H., & Sharpless, N. E. (2013) · Cell · doi:10.1016/j.cell.2012.12.010 · Cited by 419
“In accord with prior results (Krimpenfort et al., 2001; Sharpless et al., 2001), MEFs of each genotype displayed similar growth kinetics at early passage (Figure S1C).”
Putting the stress on senescence
Serrano, M., & Blasco, M. A. (2001) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00278-7 · Cited by 413
Mechanisms and Regulation of Cellular Senescence
Roger, L., Tomas, F., & Gire, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313173 · Cited by 395
When cells get stressed: an integrative view of cellular senescence
Ben-Porath, I., & Weinberg, R. A. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420663 · Cited by 404
Hypersensitivity to contact inhibition provides a clue to cancer resistance of naked mole-rat
Seluanov, A., Hine, C., Azpurua, J., Feigenson, M., Bozzella, M., Mao, Z., Catania, K. C., & Gorbunova, V. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905252106 · Cited by 381
Redox Control of the Cell Cycle in Health and Disease
Sarsour, E. H., Kumar, M. G., Chaudhuri, L., Kalen, A. L., & Goswami, P. C. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2513 · Cited by 381
“However, these animals did develop an increase in tumor incidence later in life (75, 150, 155, 164, 295).”
Oncogene-Induced Cell Senescence — Halting on the Road to Cancer
Mooi, W. J., & Peeper, D. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra062285 · Cited by 371
Self-citationMolecular Genetics of Acute Lymphoblastic Leukemia
Armstrong, S. A., & Look, A. T. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.047 · Cited by 362
Histone demethylase JMJD3 contributes to epigenetic control of INK4a/ARF by oncogenic RAS
Barradas, M., Anderton, E., Acosta, J. C., Li, S., Banito, A., Rodriguez-Niedenführ, M., Maertens, G., Banck, M., Zhou, M.-M., Walsh, M. J., et al. (2009) · Genes & Development · doi:10.1101/gad.511109 · Cited by 352
“However, Arf / cells escape from senescence, whereas Ink4a / cells do not (Kamijo et al. 1997; Krimpenfort et al. 2001; Sharpless et al. 2001, 2004).”
BackgroundMechanisms of cellular senescence in human and mouse cells.
Itahana, K., Campisi, J., & Dimri, G. P. (2004) · Biogerontology · doi:10.1023/b:bgen.0000017682.96395.10 · Cited by 338
“It has been suggested that the p16/pRb pathway does not contribute to senescence in MEFs because MEFs derived from pRb or p16 null mice senesce similar to wild type MEFs in 20% O2 (Sherr and DePinho 2000; Krimpenfort et al. 2001; Sharpless et al. 2001).”
BackgroundRheinwald, J. G., Hahn, W. C., Ramsey, M. R., Wu, J. Y., Guo, Z., Tsao, H., De Luca, M., Catricalà, C., & O'Toole, K. M. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.14.5157-5172.2002 · Cited by 338
“Several studies, culminating in recent reports comparing the proliferation potential and spontaneous immortalization frequency of murine embryo fibroblasts cultured from normal, p16-null, and ARF-null mice (32, 62), have demonstrated clearly that upregulation of ARF, reinforced by coordinate upregulation of p16, is re…”
BackgroundGenetics of melanoma predisposition
Hayward, N. K. (2003) · Oncogene · doi:10.1038/sj.onc.1206445 · Cited by 321
“Interestingly, in the study of Krimpenfort et al. (2001), when the p16 null mice were crossed with Arf hemizygotes, 50% of the animals developed melanomas after treatment with the carcinogen 7, 12-dimethylbenz(a)anthracene, compared to 8% of the mice lacking just p16.”
BackgroundBruggeman, S. W. M., Valk-Lingbeek, M. E., van der Stoop, P. P. M., Jacobs, J. J. L., Kieboom, K., Tanger, E., Hulsman, D., Leung, C., Arsenijevic, Y., Marino, S., et al. (2005) · Genes & Development · doi:10.1101/gad.1299305 · Cited by 315
“…lymphocyte counts and flow cytometry Bmi1+/− FVB or C57BL/6 mice (Van der Lugt et al. 1994) were crossed with Ink4a/Arf +/− FVB mice (Serrano et al. 1996), with Arf +/− FVB mice (Kamijo et al. 1997), with p53+/− FVB mice (Donehower et al. 1992), or Ink4a+/− C57BL/6 mice (Krimpenfort et al. 2001).”
MethodCells exhibiting strong p16 INK4a promoter activation in vivo display features of senescence
Liu, J.-Y., Souroullas, G. P., Diekman, B. O., Krishnamurthy, J., Hall, B. M., Sorrentino, J. A., Parker, J. S., Sessions, G. A., Gudkov, A. V., & Sharpless, N. E. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1818313116 · Cited by 306
Delmas, V., Beermann, F., Martinozzi, S., Carreira, S., Ackermann, J., Kumasaka, M., Denat, L., Goodall, J., Luciani, F., Viros, A., et al. (2007) · Genes & Development · doi:10.1101/gad.450107 · Cited by 311
“Concordantly, bcatsta by itself was insufficient to induce melanoma in mice; this is similar to p16INK4a (Serrano et al. 1996; Krimpenfort et al. 2001; Sharpless et al. 2001), the deletion of which does not lead to melanoma formation if not assisted by additional oncogenes.”
BackgroundThe Molecular and Genetic Basis of Neurological Tumours
Zhu, Y., & Parada, L. F. (2002) · Nature Reviews Cancer · doi:10.1038/nrc866 · Cited by 309
“cgi?l=12578">Ink4a -homozygous nor Ink4a-heterozygous mice develop astrocytomas, although they are cancer pron”
BackgroundAckermann, J., Frutschi, M., Kaloulis, K., McKee, T., Trumpp, A., & Beermann, F. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2970 · Cited by 306
Mouse models for human lung cancer
Meuwissen, R., & Berns, A. (2005) · Genes & Development · doi:10.1101/gad.1284505 · Cited by 302
“As a starting point, one might use mice that combine a conditional K-Ras or Myc oncogene with conditional tumor-suppressor genes such as Trp53 or p16Ink4a/p19ARF (Vooijs et al. 1998; Jonkers et al. 2001; Krimpenfort et al. 2001; Jonkers and Berns 2002) that are frequently mutated in lung tumors.”
Self-citationThe genetics of malignant melanoma: lessons from mouse and man
Chin, L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1145 · Cited by 302
“Interestingly, animals that are specifically deficient for Ink4a show a low frequency of melanoma spontaneously or after carcinogen treatment with DMBA (7,12-dimethylbenzanthracene”
BackgroundHunter, K. W., Crawford, N. P., & Alsarraj, J. (2008) · Breast Cancer Research · doi:10.1186/bcr1988 · Cited by 298
Senescence, apoptosis and therapy — cutting the lifelines of cancer
Schmitt, C. A. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1044 · Cited by 295
“By contrast, defects in the INK4A/RB pathway have no significant impact on tumour development in the context of activated MY”
BackgroundTargeting senescent cells in translational medicine
Paez‐Ribes, M., González‐Gualda, E., Doherty, G. J., & Muñoz‐Espín, D. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201810234 · Cited by 293
“A relevant concern is that bypassing or reversing senescence could indeed promote tumorigenesis (Krimpenfort et al, 2001).”
BackgroundUhrbom, L., Dai, C., Celestino, J., Rosenblum, M. K., Fuller, G. N., & Holland, E. C. (2002) · PubMed · Cited by 322
Sakamoto, K. M., & Frank, D. A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1137 · Cited by 279
p15Ink4b is a critical tumour suppressor in the absence of p16Ink4a
Krimpenfort, P., IJpenberg, A., Song, J.-Y., van der Valk, M., Nawijn, M., Zevenhoven, J., & Berns, A. (2007) · Nature · doi:10.1038/nature06084 · Cited by 269
Self-citationBRAFE600 in benign and malignant human tumours
Michaloglou, C., Vredeveld, L. C. W., Mooi, W. J., & Peeper, D. S. (2008) · Oncogene · doi:10.1038/sj.onc.1210704 · Cited by 275
“, 1996) and p16 knockout mice treated with DMBA develop, among other tumours, melanoma (Krimpenfort et al., 2001; Sharpless et al., 2001).”
BackgroundSelf-citationThe Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma
Sheppard, K. E., & McArthur, G. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0259 · Cited by 265
“Loss of p16 in mice is not sufficient to induce melanoma but does mimic the melanoma predisposition seen in humans (45, 46).”
BackgroundThe INK4a/ARF locus and melanoma
Sharpless, N. E., & Chin, L. (2003) · Oncogene · doi:10.1038/sj.onc.1206461 · Cited by 261
“Mice lacking p16INK4a are phenotypically normal except prone to tumors and sensitive to carcinogens (see below and Krimpenfort et al., 2001; Sharpless et al., 2001).”
BackgroundRuivenkamp, C. A. L., van Wezel, T., Zanon, C., Stassen, A. P. M., Vlcek, C., Csikós, T., Klous, A. M., Tripodis, N., Perrakis, A., Boerrigter, L., et al. (2002) · Nature Genetics · doi:10.1038/ng903 · Cited by 259
“Similar results have been observed in p19 Arf (ref”
ResultSelf-citationLinggi, B., Müller-Tidow, C., van de Locht, L., Hu, M., Nip, J., Serve, H., Berdel, W. E., van der Reijden, B., Quelle, D. E., Rowley, J. D., et al. (2002) · Nature Medicine · doi:10.1038/nm726 · Cited by 258
“Specific loss of either p19 ARF or p16 INK4a in mice predisposes these animals to a wide range of tumor”
BackgroundReversal of Senescence in Mouse Fibroblasts through Lentiviral Suppression of p53
Dirac, A. M. G., & Bernards, R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c300023200 · Cited by 255
Cellular senescence and cancer treatment
Schmitt, C. A. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.08.005 · Cited by 254
Toward a Molecular Classification of Melanoma
Fecher, L. A., Cummings, S. D., Keefe, M. J., & Alani, R. M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.0442 · Cited by 252
Cdk2 suppresses cellular senescence induced by the c-myc oncogene
Campaner, S., Doni, M., Hydbring, P., Verrecchia, A., Bianchi, L., Sardella, D., Schleker, T., Perna, D., Tronnersjö, S., Murga, M., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2004 · Cited by 251
“Although neither p21 Cip1 nor p16 INK4a function as tumour suppressors in Eμ- myc Cdk2 +/+ mic”
BackgroundA cellular hierarchy in melanoma uncouples growth and metastasis
Karras, P., Bordeu, I., Pozniak, J., Nowosad, A., Pazzi, C., Van Raemdonck, N., Landeloos, E., Van Herck, Y., Pedri, D., Bervoets, G., et al. (2022) · Nature · doi:10.1038/s41586-022-05242-7 · Cited by 247
Toll-like receptors as key mediators in innate antifungal immunity
Roeder, A., Kirschning, C. J., Rupec, R. A., Schaller, M., Weindl, G., & Korting, H. C. (2004) · Medical Mycology · doi:10.1080/13693780400011112 · Cited by 250
Swanton, C. (2004) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01321-4 · Cited by 248
Tumor suppressor genes in normal and malignant hematopoiesis
Krug, U., Ganser, A., & Koeffler, H. P. (2002) · Oncogene · doi:10.1038/sj.onc.1205322 · Cited by 231
“Mice with a disruption of both alleles of p16INK4A and Oncogene an intact p19ARF (p16INK4A7/7/p19ARF+/+) have a moderately increased cancer susceptibility (Krimpenfort et al., 2001; Sharpless et al., 2001).”
BackgroundOverlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis
Wilting, R. H., Yanover, E., Heideman, M. R., Jacobs, H., Horner, J., van der Torre, J., DePinho, R. A., & Dannenberg, J. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.136 · Cited by 226
“Mice were killed 4–10 days after the last injection. p21 / and Cdkn2a / mice have been described before (Deng et al, 1995; Krimpenfort et al, 2001).”
MethodThe differential impact of p16INK4a or p19ARF deficiency on cell growth and tumorigenesis
Sharpless, N. E., Ramsey, M. R., Balasubramanian, P., Castrillon, D. H., & DePinho, R. A. (2004) · Oncogene · doi:10.1038/sj.onc.1207074 · Cited by 224
“…encoded by the Ink4a/Arf locus encodes tumor-suppressor activity appears definitively resolved by the collective experimental evidence of this report and others (Kamijo et al., 1997, 1999; Krimpenfort et al., 2001; Sharpless et al., 2001a, 2002, 2003; Bachoo et al., 2002; Kannan et al., 2003).”
BackgroundResultInfluentialSonic hedgehog acts at multiple stages during pancreatic tumorigenesis
Morton, J. P., Mongeau, M. E., Klimstra, D. S., Morris, J. P., Lee, Y. C., Kawaguchi, Y., Wright, C. V. E., Hebrok, M., & Lewis, B. C. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701158104 · Cited by 223
INK4a‐deficient human diploid fibroblasts are resistant to RAS‐induced senescence
Brookes, S., Rowe, J., Ruas, M., Llanos, S., Clark, P. A., Lomax, M., James, M. C., Vatcheva, R., Bates, S., Vousden, K. H., et al. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf289 · Cited by 220
Haploinsufficiency for tumour suppressor genes: when you don't need to go all the way
Santarosa, M., & Ashworth, A. (2004) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2004.01.001 · Cited by 218
Rad, R., Cadiñanos, J., Rad, L., Varela, I., Strong, A., Kriegl, L., Constantino-Casas, F., Eser, S., Hieber, M., Seidler, B., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.05.014 · Cited by 216
“To study the effect of p16Ink4a inactivation in vivo, we used p16Ink4a* mice, which have a point mutation that is silent in the p19Arf reading frame but introduces a stop codon in p16Ink4a (Krimpenfort et al., 2001).”
MethodWide spectrum of tumors in knock‐in mice carrying a Cdk4 protein insensitive to INK4 inhibitors
Sotillo, R., Dubus, P., Martn, J., de la Cueva, E., Ortega, S., Malumbres, M., & Barbacid, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.23.6637 · Cited by 208
Polycomb repression: from cellular memory to cellular proliferation and cancer
Jacobs, J. J. L., & van Lohuizen, M. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00052-5 · Cited by 209
Young, R. J., Waldeck, K., Martin, C., Foo, J. H., Cameron, D. P., Kirby, L., Do, H., Mitchell, C., Cullinane, C., Liu, W., et al. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12228 · Cited by 206
Melk, A., Kittikowit, W., Sandhu, I., Halloran, K. M., Grimm, P., Schmidt, B. M. W., & Halloran, P. F. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00032.x · Cited by 205
“Reated -galactosidase (SA- -GAL) and lipofuscin [16–19].”
Melanoma genetics and the development of rational therapeutics
Chudnovsky, Y., Khavari, P. A., & Adams, A. E. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200524808 · Cited by 204
“clarify the roles of the 2 genes encoded by this locus, mice with a selective knockout of the Arf gene (93, 94) or the Ink4a gene (95, 96) were generated and determined to be cancer prone.”
BackgroundHeterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors
Chen, W. Y., Zeng, X., Carter, M. G., Morrell, C. N., Chiu Yen, R.-W., Esteller, M., Watkins, D. N., Herman, J. G., Mankowski, J. L., & Baylin, S. B. (2003) · Nature Genetics · doi:10.1038/ng1077 · Cited by 201
“16 ), it seems stronger than that observed for other important ones, such as Cdkn2a (refs”
BackgroundCDK4: A Key Player in the Cell Cycle, Development, and Cancer
Baker, S. J., & Reddy, E. P. (2012) · Genes & Cancer · doi:10.1177/1947601913478972 · Cited by 194
The tumor-suppressive functions of the human INK4A locus
Voorhoeve, P. M., & Agami, R. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00223-x · Cited by 194
Regulation of G1 cell-cycle progression by oncogenes and tumor suppressor genes
Ho, A. (2002) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(01)00263-5 · Cited by 192
Tumor Stroma-Derived TGF-β Limits Myc-Driven Lymphomagenesis via Suv39h1-Dependent Senescence
Reimann, M., Lee, S., Loddenkemper, C., Dörr, J. R., Tabor, V., Aichele, P., Stein, H., Dörken, B., Jenuwein, T., & Schmitt, C. A. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.043 · Cited by 184
Senescence promotes in vivo reprogramming through p16INK4a and IL‐6
Mosteiro, L., Pantoja, C., de Martino, A., & Serrano, M. (2018) · Aging Cell · doi:10.1111/acel.12711 · Cited by 182
“Reprogrammable i4F-B mice were crossed with mutant mice for Ink4a/Arf, Ink4a (Krimpenfort et al., 2001), Arf (Kamijo et al.”
BackgroundThe ARF tumor suppressor: Structure, functions and status in cancer
Ozenne, P., Eymin, B., Brambilla, E., & Gazzeri, S. (2010) · International Journal of Cancer · doi:10.1002/ijc.25511 · Cited by 183
“In contrast, p16-null MEFs display a phenotype similar to wild-type MEFs and are not sensitive to Ha-ras transformation.(3,4) Although these observations in MEFs do not apply to all cell types, they highlight ARF as a bona fide tumor suppressor per se, independent from p16.”
BackgroundCellular Senescence Limits Regenerative Capacity and Allograft Survival
Braun, H., Schmidt, B. M. W., Raiss, M., Baisantry, A., Mircea-Constantin, D., Wang, S., Gross, M.-L., Serrano, M., Schmitt, R., & Melk, A. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011100967 · Cited by 179
p16Ink4a in Melanocyte Senescence and Differentiation
Sviderskaya, E. V. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.6.446 · Cited by 179
CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma
Salvador-Barbero, B., Álvarez-Fernández, M., Zapatero-Solana, E., El Bakkali, A., Menéndez, M. D. C., López-Casas, P. P., Di Domenico, T., Xie, T., VanArsdale, T., Shields, D. J., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.01.007 · Cited by 176
Advances in imaging mouse tumour models in vivo
Lyons, S. K. (2005) · The Journal of Pathology · doi:10.1002/path.1697 · Cited by 174
“Aspects that underlie the molecular basis of human cancer are also well addressed and mouse models have provided an essential means with which to elucidate the involvement and in vivo effects of various genetic lesions in tumourigenesis, tumour progression, and metastasis [1–5].”
BackgroundEpigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis
Chen, W., Cooper, T. K., Zahnow, C. A., Overholtzer, M., Zhao, Z., Ladanyi, M., Karp, J. E., Gokgoz, N., Wunder, J. S., Andrulis, I. L., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.030 · Cited by 165
Cyclins and CDKS in development and cancer: lessons from genetically modified mice
Santamaria, D. (2006) · Frontiers in Bioscience · doi:10.2741/1871 · Cited by 165
Invasive melanoma in Cdk4-targeted mice
Sotillo, R., García, J. F., Ortega, S., Martín, J., Dubus, P., Barbacid, M., & Malumbres, M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.241338598 · Cited by 164
Elimination of p19ARF-expressing cells enhances pulmonary function in mice
Hashimoto, M., Asai, A., Kawagishi, H., Mikawa, R., Iwashita, Y., Kanayama, K., Sugimoto, K., Sato, T., Maruyama, M., & Sugimoto, M. (2016) · JCI Insight · doi:10.1172/jci.insight.87732 · Cited by 162
“Embryonic fibroblasts prepared from these mice (MEFs) expressed p19ARF, p16INK4a, p21, and luciferase when senescence was induced by either serial passages or oncogenic Ras (Figure 1, B and C).”
BackgroundInfluentialKalamarides, M., Stemmer-Rachamimov, A. O., Niwa-Kawakita, M., Chareyre, F., Taranchon, E., Han, Z.-Y., Martinelli, C., Lusis, E. A., Hegedus, B., Gutmann, D. H., et al. (2011) · Oncogene · doi:10.1038/onc.2010.609 · Cited by 162
“The p53flox/flox (Marino et al., 2000) and p16ink4a / (Krimpenfort et al., 2001) mice were kindly provided by A Berns.”
MethodBulavin, D. V., Kovalsky, O., Hollander, M. C., & Fornace, A. J. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.11.3859-3871.2003 · Cited by 161
“Another required component for H-ras growth arrest is Gadd45a, which is known to be regulated by p53 (28).”
BackgroundMethodInfluential
Metadata
- Authors
- Krimpenfort, P., Quon, K. C., Mooi, W. J., Loonstra, A., & Berns, A.
- Affiliations
- The Netherlands Cancer Institute (NL)
- Corresponding author
- Berns, Anton
- Venue
- Nature
- Published
- 2001-09
- Volume
- 413
- Issue
- 6851
- Pages
- 83-86
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2003223749
- Cited by
- 568
- References
- 27
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 27 · 2023: 9 · 2022: 9 · 2021: 14 · 2020: 10 · 2019: 12 · 2018: 7 · 2017: 14 · 2016: 7 · 2015: 13 · 2014: 20 · 2013: 22 · 2012: 12
- FWCI
- 25.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- p16INK4a, CDKN2A, p14ARF, metastatic melanoma, cancer susceptibility, tumor suppressor, germline mutations, melanoma predisposition, DMBA-induced carcinogenesis, embryonic fibroblasts, mouse model
- MeSH terms
- Animals, Carcinogens, Cell Transformation, Neoplastic, Cells, Cultured, Embryo, Mammalian, Female, Fibroblasts, Humans, Male, Melanoma, Experimental, Proteins, Genes, ras, 9,10-Dimethyl-1,2-benzanthracene, Gene Deletion, Point Mutation, Cyclin-Dependent Kinase Inhibitor p16, Genes, p16, Genetic Predisposition to Disease, Tumor Suppressor Protein p14ARF, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.